Research and Clinical Trials

Brief Description  
With an estimated 33.2 million people in the world infected with the virus, human immunodeficiency virus (HIV) is a major medical problem. The purpose of this study is to evaluate the safety of a new medication (GSK1349572) in HIV infected individuals who have never taken antiretroviral medications before. This study is also comparing the efficacy of GSK1349572 + epzicom to Atripla which is currently one of the medications used for HIV therapy.
Who may be Eligible  

You may be eligible if you:
  1. Are an HIV infected individual who is 18 years old or older
  2. Have never taken HIV medications.
  3. Have a viral load >1000 copies/mL
  4. You are not pregnant or breastfeeding or planning on becoming pregnant during the term of the trial (96 weeks).
  5. Not have a positive HLA-B*5701 which is verified by your doctor
  6. Have no active AIDS defining illness at your first study visit.
  7. Have not received an HIV-1 vaccine in the past 90 days
  8. Do not meet criteria of exclusion based on your routine lab results
  9. Do not have a history of cancer in the past 5 years
  10. Will not be treated for hepatitis C during the study term.
  11. Have not received an experimental medication within 28 days
IRB Number  
Principal Investigator  
Johnson, Marc

For More Information, Contact  Jessica  A, Kearney-Bryan
Phone:  (704) 355-0244  Fax:  (704) 446-7641  
Address:3rd Floor Myers Park Clinic 1350 South King's Drive Charlotte, NC 28207